Skip to content

Tarsus Pharmaceuticals, Inc.

TARS· NasdaqCore metricsCIK 1819790

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · +0.12%
Market cap
$3.79B
49.31M shares
Filings
679
$194.57M
Q3 2026+146.7% FY25 yoy
-$668.33M
Q3 2026N/M FY25 yoy
-$662.09M
Q3 2026N/M FY25 yoy
$19.47M
Q3 2026derivedN/M FY25 yoy
-$14.40
Q3 2026N/M FY25 yoy
$136.53M
Q3 2026+93.7% FY25 yoy
$3.79B
—
5.6×
36.4×
0.86%
—

Twelve months to Sep 30, 2026 · derived

Price

$76.89+1.77%+$1.34past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$451.36MFY 2025
$451.36M0FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$451,360,000reported
FY 20242024-12-31$182,953,000reported
FY 20232023-12-31$17,447,000reported
FY 20222022-12-31$25,816,000reported
FY 20212021-12-31$57,027,000reported
FY 20202020-12-31$0reported

Segments

Products
Revenue by Products, FY2020 to FY2025FY2020FY2021Collaboration revenue · FY2021 · $3.96MLicense fees · FY2021 · $53.07MFY2022Collaboration revenue · FY2022 · $1.92MLicense fees · FY2022 · $23.89MLicense fees and collaboration revenue · FY2022 · $25.82MFY2023Product sales, net · FY2023 · $14.73MLicense fees and collaboration revenue · FY2023 · $2.72MLicense And Collaboration, Other · FY2023 · $200.00KLicense fees and collaboration revenue · FY2023 · $2.72MFY2024Product sales, net · FY2024 · $180.06MLicense fees and collaboration revenue · FY2024 · $2.89MLicense fees and collaboration revenue · FY2024 · $2.89MFY2025Product sales, net · FY2025 · $451.36M
LineFY2025ShareChange
Product sales, net$451.36M100%+150.7%
License fees and collaboration revenue$0.00—−100.0%
Collaboration revenue———
License And Collaboration, Other———
License fees———
License fees and collaboration revenue———
Total$451.36M

From the 10-K filed Feb 23, 2026TARS

Biological products, except diagnostic substances

Tarsus Pharmaceuticals, Inc. is the 16th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Tarsus Pharmaceuticals, Inc. · CIK 1819790 · Engraved from SEC EDGAR